Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

41.64 -0.71 (-1.68%) As of 09:45AM CST. Market open.

Jiangsu Hengrui Medicine Co., Ltd.

No. 38, Huanghe Road
Economic and Technological Development Zone
Lianyungang 222000
China

https://www.hrs.com.cn

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Hong Bin Dai	GM & Director	N/A	N/A	1976
Mr. Jianjun Liu	Financial Director	N/A	N/A	1978
Mr. Jie Ping Sun	Deputy GM & Director	N/A	N/A	1970
Dr. Lian Shan Zhang Ph.D.	Deputy GM & Director	N/A	N/A	1962
Ms. Xiao Han Liu	Secretary of the Board of Directors	N/A	N/A	1985
Ms. Su Mei Jiang	Deputy General Manager	N/A	N/A	1965
Mr. Ya Ping Shen	Deputy General Manager	N/A	N/A	1964
Mr. Cheng Liao	Deputy General Manager	N/A	N/A	1975
Mr. Hongsen Wang	Deputy General Manager	N/A	N/A	1970
Mr. Feng He	Deputy General Manager	N/A	N/A	1967

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China.

Corporate Governance

Jiangsu Hengrui Medicine Co., Ltd.’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.